Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and Economic Value of Reducing Antimicrobial Resistance in the Management of Hospital-Acquired Infections with Limited Treatment Options in Greece.
Barmpouni M, Gordon JP, Miller RL, Dennis JW, Grammelis V, Rousakis A, Souliotis K, Poulakou G, Daikos GL, Al-Taie A. Barmpouni M, et al. Among authors: daikos gl. Infect Dis Ther. 2023 Jul;12(7):1891-1905. doi: 10.1007/s40121-023-00837-7. Epub 2023 Jul 6. Infect Dis Ther. 2023. PMID: 37410343 Free PMC article.
The Use and Effectiveness of Ceftazidime-Avibactam in Real-World Clinical Practice: EZTEAM Study.
Soriano A, Montravers P, Bassetti M, Klyasova G, Daikos G, Irani P, Stone G, Chambers R, Peeters P, Shah M, Hulin C, Albuquerque N, Basin E, Gaborit B, Kourbeti I, Menichetti F, Perez-Rodriguez MT, Pletz MW, Sanchez M, Trompa I, Verma A, de Figueiredo MLN, Charbonneau C. Soriano A, et al. Infect Dis Ther. 2023 Mar;12(3):891-917. doi: 10.1007/s40121-023-00762-9. Epub 2023 Feb 10. Infect Dis Ther. 2023. PMID: 36763243 Free PMC article.
Prevalence and Clinical Consequences of Colistin Heteroresistance and Evolution into Full Resistance in Carbapenem-Resistant Acinetobacter baumannii.
Kon H, Hameir A, Nutman A, Temkin E, Keren Paz A, Lellouche J, Schwartz D, Weiss DS, Kaye KS, Daikos GL, Skiada A, Durante-Mangoni E, Dishon Benattar Y, Yahav D, Daitch V, Bernardo M, Iossa D, Friberg LE, Theuretzbacher U, Leibovici L, Dickstein Y, Pollak D, Mendelsohn S, Paul M, Carmeli Y. Kon H, et al. Among authors: daikos gl. Microbiol Spectr. 2023 Jun 15;11(3):e0509322. doi: 10.1128/spectrum.05093-22. Epub 2023 May 23. Microbiol Spectr. 2023. PMID: 37219426 Free PMC article.
Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA).
Pérez-Galera S, Bravo-Ferrer JM, Paniagua M, Kostyanev T, de Kraker MEA, Feifel J, Sojo-Dorado J, Schotsman J, Cantón R, Daikos GL, Carevic B, Dragovac G, Tan LK, Raka L, Hristea A, Viale P, Akova M, Reguera JM, Valiente de Santis L, Torre-Cisneros J, Cano Á, Roilides E, Radulovic L, Kirakli C, Shaw E, Falagas ME, Pintado V, Goossens H, Bonten MJ, Gutiérrez-Gutiérrez B, Rodriguez-Baño J; COMBACTE-CARE-EURECA Team. Pérez-Galera S, et al. Among authors: daikos gl. EClinicalMedicine. 2023 Feb 27;57:101871. doi: 10.1016/j.eclinm.2023.101871. eCollection 2023 Mar. EClinicalMedicine. 2023. PMID: 36895801 Free PMC article.
Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial.
Carmeli Y, Cisneros JM, Paul M, Daikos GL, Wang M, Torre-Cisneros J, Singer G, Titov I, Gumenchuk I, Zhao Y, Jiménez-Rodríguez RM, Liang L, Chen G, Pyptiuk O, Aksoy F, Rogers H, Wible M, Arhin FF, Luckey A, Leaney JL, Pypstra R, Chow JW; COMBACTE-CARE consortium REVISIT study group. Carmeli Y, et al. Among authors: daikos gl. Lancet Infect Dis. 2024 Oct 7:S1473-3099(24)00499-7. doi: 10.1016/S1473-3099(24)00499-7. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39389071
Assessment of De-Escalation of Empirical Antimicrobial Therapy in Medical Wards with Recognized Prevalence of Multi-Drug-Resistant Pathogens: A Multicenter Prospective Cohort Study in Non-ICU Patients with Microbiologically Documented Infection.
Rapti V, Poulakou G, Mousouli A, Kakasis A, Pagoni S, Pechlivanidou E, Masgala A, Sympardi S, Apostolopoulos V, Giannopoulos C, Alexiou N, Arvaniti K, Trakatelli C, Prionas A, Samarkos M, Daikos GL, Giamarellou H. Rapti V, et al. Among authors: daikos gl. Antibiotics (Basel). 2024 Aug 27;13(9):812. doi: 10.3390/antibiotics13090812. Antibiotics (Basel). 2024. PMID: 39334987 Free PMC article.
Risk factors for bloodstream infections due to carbapenem-resistant Enterobacterales: a nested case-control-control study.
Zhou H, Buetti N, Pérez-Galera S, Bravo-Ferrer J, Gutiérrez-Gutiérrez B, Paniagua-García M, Feifel J, Sauser J, Kostyanev T, Canton R, Tan LK, Basoulis D, Pintado V, Roilides E, Dragovac G, Torre-Cisneros J, Mediç D, Akova M, Goossens H, Bonten M, Harbarth S, Rodriguez-Baño J, De Kraker MEA; COMBACTE- EURECA project team. Zhou H, et al. J Antimicrob Chemother. 2024 Sep 3;79(9):2132-2141. doi: 10.1093/jac/dkae157. J Antimicrob Chemother. 2024. PMID: 38988305 Free PMC article.
Integration of individual preclinical and clinical anti-infective PKPD data to predict clinical study outcomes.
Aranzana-Climent V, van Os W, Nutman A, Lellouche J, Dishon-Benattar Y, Rakovitsky N, Daikos GL, Skiada A, Pavleas I, Durante-Mangoni E, Theuretzbacher U, Paul M, Carmeli Y, Friberg LE. Aranzana-Climent V, et al. Among authors: daikos gl. Clin Transl Sci. 2024 Jul;17(7):e13870. doi: 10.1111/cts.13870. Clin Transl Sci. 2024. PMID: 38952168 Free PMC article. Clinical Trial.
225 results